Summary by Moomoo AI
Tharimmune reported financial results for fiscal year 2024, with R&D expenses increasing 80% to $6.4 million from $3.6 million in 2023, driven by clinical trial costs for TH104 and license fees. Net loss widened to $12.2 million compared to $9.3 million in 2023. The company ended the year with $3.6 million in cash.Key operational highlights included completion of a Phase 1 trial for TH104 showing favorable pharmacokinetics and safety profile, with plans to initiate a Phase 2 trial in primary biliary cholangitis patients in 2025. The company also expanded its pipeline through strategic licensing deals with Avior Bio for TH104/TH103 and Intract Pharma for oral TNF-α antibody TH023.Looking ahead, Tharimmune plans to advance multiple clinical programs in 2025, including a hepatic impairment study and Phase 2 trial for TH104, while progressing IND-enabling studies for early-stage candidates HS3215 and HS1940. Management noted that additional funding will be required to support future operations, with current resources raising substantial doubt about the company's ability to continue as a going concern.
Comment(0)
Reason For Report